Trial Condition(s):

Macular degeneration

EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] post-marketing surveillance in Japan

Bayer Identifier:

16656

ClinicalTrials.gov Identifier:

NCT01756261

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) and compared at baseline and at the 6 and 12 months after start of EYLEA treatment.

Inclusion Criteria
- Patients who have been determined to start EYLEA treatment
 - Patients who are registered to Special drug use investigation of EYLEA for AMD(Trial Number 15858)
 - Patients who have agreed with the patient informed consent
Exclusion Criteria
- Patients who have already received EYLEA

Trial Summary

Enrollment Goal
757
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design